AI-assisted, source-referenced information. Independent clinical review is pending. Our standards.
The short answer

A medicine being licensed does not mean everyone can receive it on the NHS. Regulatory authorisation, funding guidance, local delivery and an individual prescribing assessment answer different questions.

Authorisation defines permitted uses

The MHRA assesses medicines for quality, safety and effectiveness. The UK weight-management authorisations describe eligible populations and conditions of use. Wegovy tablets were authorised in June 2026 and Foundayo in August 2026, so an older article saying all UK GLP-1 weight treatments are injections is no longer current.

Authorisation is not a personal eligibility decision. A clinician still needs to consider medical history, other medicines, pregnancy plans, prior treatment and practical needs. Nor does an authorised product necessarily have stock at every pharmacy or an NHS-funded pathway in every part of the UK.

Sources: MHRA: First GLP-1 tablet for weight loss approved in the UK; MHRA: UK authorises orforglipron for weight management and type 2 diabetes; MHRA: GLP-1 medicines for weight loss and diabetes: what you need to know

NHS recommendations can be narrower

NICE's tirzepatide weight-management recommendation uses an initial BMI of at least 35 plus a weight-related condition, with lower thresholds for specified ethnic family backgrounds. NHS England also has a phased implementation policy. Meeting the marketing authorisation therefore does not establish access through the current local NHS pathway.

NICE's established semaglutide weight-management recommendation has its own specialist-service criteria and treatment-duration conditions. Do not transplant those rules automatically to a new tablet or another medicine. Always identify which formulation, indication and guidance document an eligibility statement concerns.

Sources: NICE: TA1026: Tirzepatide for managing overweight and obesity; NICE: TA875: Semaglutide for managing overweight and obesity; NHS England: Interim commissioning guidance for tirzepatide

Your location and service pathway matter

England's commissioning arrangements should not be presented as a UK-wide rule. Scotland, Wales and Northern Ireland have their own service and funding arrangements. Even within England, a phased rollout means that the practical route and assessment capacity need to be checked locally. Ask the GP practice or weight-management service what currently applies.

For a newer treatment, distinguish an expected appraisal date from published guidance. A calendar entry is not a funding decision. The Scottish Medicines Consortium's September 2026 advice on semaglutide tablets, for example, was a non-submission position, separate from the MHRA licence. Read the actual decision and its date rather than relying on a launch headline.

Sources: NHS England: Weight management injections: NHS England patient information; NHS England: Interim commissioning guidance for tirzepatide; Scottish Medicines Consortium: Semaglutide tablets: NHS Scotland non-submission advice, September 2026

Private prescribing still requires clinical assessment

Paying privately does not remove the need for a proper assessment or make a requested prescription automatic. Check the service, prescriber and dispensing pharmacy through their relevant regulators. Be prepared to supply accurate medical information and allow the checks the service needs to make. A provider that asks for more information may be resolving a genuine clinical question.

Ask what follow-up is included and whether your usual healthcare team will receive a treatment summary with your consent. Keep your own record of medicine, strength and dates. This is particularly useful when another clinician treats an illness or prescribes a new medicine.

Sources: General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online; MHRA: MHRA warns against buying weight loss medicines without a prescription

Plan any transfer instead of assuming continuation

A private prescription does not automatically create entitlement to NHS continuation. Ask the local service to assess eligibility and explain its pathway before relying on a transfer. If another private service is taking over, it may need a fresh assessment and evidence of the current treatment. Buying a refill is not the same as transferring clinical responsibility.

Request a concise treatment summary covering the starting indication, dose history, response, adverse effects and last dose. Confirm who will handle the next review and prescription. If there may be a gap, ask the prescriber what to do rather than independently restarting from an old supply.

Sources: NHS England: Weight management injections: NHS England patient information; General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online; NICE: Prescribing, reviewing and stopping tirzepatide

Questions, answered.

Does MHRA approval mean the NHS must prescribe a medicine immediately?

No. NHS appraisal, commissioning and individual assessment are separate steps from marketing authorisation.

Sources: MHRA: UK authorises orforglipron for weight management and type 2 diabetes; NHS England: Interim commissioning guidance for tirzepatide

Can paying privately bypass clinical suitability checks?

Sources & further reading

Original sources for this guide. Source checks are not independent clinical review.

  1. First GLP-1 tablet for weight loss approved in the UKMHRA · Accessed 19 November 2026
  2. UK authorises orforglipron for weight management and type 2 diabetesMHRA · Accessed 19 November 2026
  3. GLP-1 medicines for weight loss and diabetes: what you need to knowMHRA · Accessed 19 November 2026
  4. TA1026: Tirzepatide for managing overweight and obesityNICE · Accessed 19 November 2026
  5. TA875: Semaglutide for managing overweight and obesityNICE · Accessed 19 November 2026
  6. Interim commissioning guidance for tirzepatideNHS England · Accessed 19 November 2026
  7. Weight management injections: NHS England patient informationNHS England · Accessed 19 November 2026
  8. Semaglutide tablets: NHS Scotland non-submission advice, September 2026Scottish Medicines Consortium · Accessed 19 November 2026
  9. How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
  10. MHRA warns against buying weight loss medicines without a prescriptionMHRA · Accessed 19 November 2026
  11. Prescribing, reviewing and stopping tirzepatideNICE · Accessed 19 November 2026